| Literature DB >> 29748486 |
Juan Andrés Rubiolo1,2, Carmen Vale3, Andrea Boente-Juncal4, Masahiro Hirama5, Shuji Yamashita6, Mercedes Camiña7, Mercedes R Vieytes8, Luis M Botana9.
Abstract
Ciguatoxins are polyether marine toxins that act as sodium channel activators. These toxins cause ciguatera, one of the most widespread nonbacterial forms of food poisoning, which presents several symptoms in humans including long-term neurological alterations. Earlier work has shown that both acute and chronic exposure of primary cortical neurons to synthetic ciguatoxin CTX3C have profound impacts on neuronal function. Thus, the present work aimed to identify relevant neuronal genes and metabolic pathways that could be altered by ciguatoxin exposure. To study the effect of ciguatoxins in primary neurons in culture, we performed a transcriptomic analysis using whole mouse genome microarrays, for primary cortical neurons exposed during 6, 24, or 72 h in culture to CTX3C. Here, we have shown that the effects of the toxin on gene expression differ with the exposure time. The results presented here have identified several relevant genes and pathways related to the effect of ciguatoxins on neurons and may assist in future research or even treatment of ciguatera. Moreover, we demonstrated that the effects of the toxin on gene expression were exclusively consequential of its action as a voltage-gated sodium channel activator, since all the effects of CTX3C were avoided by preincubation of the neurons with the sodium channel blocker tetrodotoxin.Entities:
Keywords: ciguatera; ciguatoxin; cortical neuron; gene; tetrodotoxin
Mesh:
Substances:
Year: 2018 PMID: 29748486 PMCID: PMC5983248 DOI: 10.3390/toxins10050192
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Box-and-whisker plot of increased and decreased gene transcripts in cells treated with 5 nM CTX3C (CTX) during 6, 24, or 72 h versus control cells. Yellow-shaded boxes show the assay time analyzed in each plot. Changes in transcription between treatments for each time assayed were determined by ANOVA and fold change. Genes with p < 0.05 (n = 3) and a fold change ≥ 2 were considered significant.
Figure 2Venn diagram for CTX3C-induced genes in cortical neurons after 6, 24, or 72 h, together with those repressed after 24 h of CTX3C treatment. Color coding points to the individual conditions plotted. Intersections represent common genes affected in the corresponding conditions being compared. UP-FC: Upregulated-Fold Change; DOWN-FC: Downregulated-Fold Change.
Figure 3Biological processes significantly up- and downregulated in cortical neurons treated with 5 nM CTX3C during 6 h (A), 24 h (B), or 72 h (C). See Supplementary Table S1 for detailed information.
KEGGS pathways significantly altered by CTX in mouse primary neuron cultures.
| Term | Count | % | Genes | |
|---|---|---|---|---|
|
| ||||
|
| ||||
| mmu04360: Axon guidance | 4 | 3.77 | 0.02060781 | NM_001126047, NM_010143, NM_007937, NM_199241 |
|
| ||||
| mmu04740: Olfactory transduction | 45 | 6.52 | 7.04 × 10−6 | NM_146825, NM_146826, NM_146827, NM_146348, NM_146366, NM_146829, NM_146347, NM_147075, NM_146843, NM_147034, NM_146807, NM_147055, NM_146698, NM_146729, NM_146871, NM_147002, L08075, NM_146796, NM_146277, NM_001011531, NM_146776, NM_146523, NM_146975, NM_146895, NM_146526, NM_146525, NM_146524, NM_146691, NM_146873, NM_001011866, NM_146529, NM_147006, NM_207254, NM_146508, NM_146747, NM_146903, NM_146926, NM_146689, NM_146944, Y15524, NM_182714, NM_146644, NM_207132, NM_146311, NM_028910 |
| mmu04650: Natural killer cell-mediated cytotoxicity | 8 | 1.16 | 0.0270638 | NM_016659, NM_010649, NM_008333, NM_018729, NM_013793, NM_199022, NM_013794, AF296427, NM_014194, AF296435, NM_053152, NM_001160402 |
| mmu05332: Graft-versus-host disease | 5 | 0.72 | 0.0500518 | NM_016659, NM_008204, NM_013793, NM_014194, NM_009855, NM_053152, NM_201611 |
| mmu04640: Hematopoietic cell lineage | 6 | 0.87 | 0.05094991 | NM_001082960, NM_181858, AF296427, NM_007641, AF296435, NM_001033228, NM_001043317 |
| mmu04060: Cytokine–cytokine receptor interaction | 11 | 1.59 | 0.06837512 | NM_010228, NM_008501, NM_030712, NM_009915, NM_009916, NM_008333, NM_009835, NM_001161842, NM_007719, NM_008176, NM_021380 |
| mmu05416: Viral myocarditis | 6 | 0.87 | 0.07518154 | NM_009989, NM_008204, AK149002, AF296427, NM_009855, AF296435, NM_201611 |
| mmu05320: Autoimmune thyroid disease | 5 | 0.72 | 0.09434947 | NM_008333, NM_008204, AF296427, NM_009855, AF296435, NM_201611 |
|
| ||||
| mmu04912: GnRH signaling pathway | 7 | 1.52 | 0.0076469 | NM_027416, NM_008868, AK086722, NM_012044, NM_011109, NM_010323, AK036896 |
| mmu04370: VEGF signaling pathway | 6 | 1.30 | 0.01140765 | NM_008868, NM_177320, NM_012044, NM_011109, NM_016791, NM_001130409 |
| mmu04664: Fc epsilon RI signaling pathway | 6 | 1.30 | 0.01548986 | NM_008868, NM_008355, NM_177320, AK086722, NM_012044, NM_011109 |
| mmu00590: Arachidonic acid metabolism | 6 | 1.30 | 0.01625387 | NM_008868, NM_019455, NM_012044, NM_206537, NM_011109, AK049084 |
| mmu04270: Vascular smooth muscle contraction | 7 | 1.52 | 0.02034802 | NM_027416, NM_008868, NM_010303, NM_175441, NM_012044, NM_011109, AK036896 |
| mmu04650: Natural killer cell mediated cytotoxicity | 7 | 1.52 | 0.02188488 | NM_177320, NM_016659, NM_008333, NM_010493, NM_199022, NM_014194, NM_053152, NM_016791 |
| mmu04730: Long-term depression | 5 | 1.09 | 0.03976529 | NM_008868, NM_010303, NM_012044, NM_011109, AK036896 |
| mmu00592: Alpha-linolenic acid metabolism | 3 | 0.65 | 0.04050261 | NM_008868, NM_012044, NM_011109 |
| mmu04070: Phosphatidylinositol signaling system | 5 | 1.09 | 0.04512758 | NM_027416, NM_177320, AK038544, AK036896, AK039149 |
| mmu00591: Linoleic acid metabolism | 4 | 0.87 | 0.04889228 | NM_008868, NM_012044, NM_206537, NM_011109 |
| mmu00512: O-Glycan biosynthesis | 3 | 0.65 | 0.08379939 | NM_145218, NM_009177, NM_011371 |
| mmu04621: NOD-like receptor signaling pathway | 4 | 0.87 | 0.09955218 | NM_145857, NM_007464, NM_001033367, NM_008176 |
|
| ||||
|
| ||||
| mmu04740: Olfactory transduction | 41 | 7.69 | 5.49 × 10−6 | NM_146825, NM_146827, NM_146348, NM_146829, NM_146700, NM_146347, NM_146849, NM_146345, NM_147075, NM_207224, NM_147034, AK136433, NM_147055, NM_146698, NM_146681, NM_146861, NM_147049, NM_146890, NM_146323, L08075, NM_146796, NM_001011531, NM_146776, NM_146523, NM_146714, NM_146895, NM_147061, NM_146691, NM_146873, NM_146670, NM_147006, NM_207254, NM_146508, NM_146591, NM_010974, NM_146903, NM_146689, Y15524, NM_206823, NM_146647, NM_146749, NM_028910 |
| mmu05332: Graft-versus-host disease | 5 | 0.94 | 0.03245265 | NM_177635, NM_016659, NM_008204, NM_013793, NM_014194, NM_009855 |
| mmu05320: Autoimmune thyroid disease | 5 | 0.94 | 0.06317509 | NM_177635, NM_008333, NM_008204, AF296427, NM_009855 |
| mmu04640: Hematopoietic cell lineage | 5 | 0.94 | 0.09834101 | NM_001082960, AF296427, NM_007641, NM_001033228, NM_001043317 |
|
| ||||
| mmu04360: Axon guidance | 5 | 2.07 | 0.05239993 | NM_001126047, NM_027470, NM_010143, NM_007937, NM_199241 |
| mmu05340: Primary immunodeficiency | 3 | 1.24 | 0.05722627 | NM_001040691, NM_013482, NM_017395 |
| mmu00230: Purine metabolism | 5 | 2.07 | 0.08886492 | NM_030187, NM_011864, NM_173029, AF038896, NM_028093 |
|
| ||||
| mmu04010: MAPK signaling pathway | 10 | 4.03 | 0.00220468 | NM_001111030, NM_007540, NM_009370, NM_176933, NM_007922, NM_001081023, NM_013642, NM_008002, NM_011246, NM_010234 |
| mmu05200: Pathways in cancer | 8 | 3.23 | 0.06220855 | NM_001111030, NM_013598, NM_009370, NM_001122733, NM_008485, NM_008002, NM_011836, NM_010234 |
Figure 4Profile plot of significantly up- and downregulated genes in cortical neurons after 24 h treatment with 5 nM CTX3C, 5 nM CTX3C in combination with TTX (5 min pretreatment), and TTX alone. Lines represent expression profiles for transcripts plotted for each treatment.